Does the media refer more to AMN or OMCL?

In the previous week, Omnicell had 2 more articles in the media than AMN Healthcare Services. MarketBeat recorded 7 mentions for Omnicell and 5 mentions for AMN Healthcare Services. Omnicell's average media sentiment score of 0.94 beat AMN Healthcare Services' score of 0.35 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer WST or OMCL?

In the previous week, West Pharmaceutical Services had 4 more articles in the media than Omnicell. MarketBeat recorded 11 mentions for West Pharmaceutical Services and 7 mentions for Omnicell. Omnicell's average media sentiment score of 0.94 beat West Pharmaceutical Services' score of 0.92 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment West Pharmaceutical Services 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Omnicell 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OMCL or HSTM?

In the previous week, Omnicell had 2 more articles in the media than HealthStream. MarketBeat recorded 7 mentions for Omnicell and 5 mentions for HealthStream. HealthStream's average media sentiment score of 1.00 beat Omnicell's score of 0.94 indicating that HealthStream is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthStream 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate OMCL or MDRX?

Omnicell currently has a consensus price target of $59.86, suggesting a potential upside of 42.41%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts plainly believe Omnicell is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omnicell 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, OMCL or MDRX?

Omnicell has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.18B 1.61 $2.05M $0.44 95.53 Veradigm $1.53B 0.41 N/A N/A N/A

Is OMCL or MDRX more profitable?

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 1.67% 4.00% 2.46% Veradigm N/A N/A N/A

Does the media favor OMCL or MDRX?

In the previous week, Omnicell had 6 more articles in the media than Veradigm. MarketBeat recorded 7 mentions for Omnicell and 1 mentions for Veradigm. Veradigm's average media sentiment score of 1.58 beat Omnicell's score of 0.94 indicating that Veradigm is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradigm 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation & earnings, OMCL or HNGE?

Omnicell has higher revenue and earnings than Hinge Health. Hinge Health is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.18B 1.61 $2.05M $0.44 95.53 Hinge Health $646.34M 10.10 -$528.26M -$12.34 N/A

Is OMCL or HNGE more profitable?

Omnicell has a net margin of 1.67% compared to Hinge Health's net margin of -78.95%. Omnicell's return on equity of 4.00% beat Hinge Health's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 1.67% 4.00% 2.46% Hinge Health -78.95% -310.62% -71.08%

Does the media prefer OMCL or HNGE?

In the previous week, Hinge Health had 8 more articles in the media than Omnicell. MarketBeat recorded 15 mentions for Hinge Health and 7 mentions for Omnicell. Omnicell's average media sentiment score of 0.94 beat Hinge Health's score of 0.59 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hinge Health 9 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Omnicell (OMCL) Competitors

$42.03 +0.10 (+0.25%)

As of 10:54 AM Eastern

Compare

OMCL vs. AMN, WST, HSTM, MDRX, and HNGE

Should you buy Omnicell stock or one of its competitors? MarketBeat compares Omnicell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omnicell include AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), HealthStream (HSTM), Veradigm (MDRX), and Hinge Health (HNGE).

How does Omnicell compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

In the previous week, Omnicell had 2 more articles in the media than AMN Healthcare Services. MarketBeat recorded 7 mentions for Omnicell and 5 mentions for AMN Healthcare Services. Omnicell's average media sentiment score of 0.94 beat AMN Healthcare Services' score of 0.35 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AMN Healthcare Services currently has a consensus target price of $27.00, suggesting a potential downside of 20.54%. Omnicell has a consensus target price of $59.86, suggesting a potential upside of 42.41%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

AMN Healthcare Services has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Omnicell has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.48	-$95.70M	-$0.87	N/A
Omnicell	$1.18B	1.61	$2.05M	$0.44	95.53

Omnicell has a net margin of 1.67% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Omnicell	1.67%	4.00%	2.46%

Summary

Omnicell beats AMN Healthcare Services on 13 of the 17 factors compared between the two stocks.

How does Omnicell compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

West Pharmaceutical Services has higher revenue and earnings than Omnicell. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.07B	8.39	$493.70M	$7.48	48.83
Omnicell	$1.18B	1.61	$2.05M	$0.44	95.53

West Pharmaceutical Services has a net margin of 16.85% compared to Omnicell's net margin of 1.67%. West Pharmaceutical Services' return on equity of 19.03% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	16.85%	19.03%	14.06%
Omnicell	1.67%	4.00%	2.46%

93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 2.9% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

West Pharmaceutical Services has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

West Pharmaceutical Services currently has a consensus price target of $343.73, indicating a potential downside of 5.89%. Omnicell has a consensus price target of $59.86, indicating a potential upside of 42.41%. Given Omnicell's higher possible upside, analysts plainly believe Omnicell is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, West Pharmaceutical Services had 4 more articles in the media than Omnicell. MarketBeat recorded 11 mentions for West Pharmaceutical Services and 7 mentions for Omnicell. Omnicell's average media sentiment score of 0.94 beat West Pharmaceutical Services' score of 0.92 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
West Pharmaceutical Services	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

West Pharmaceutical Services beats Omnicell on 11 of the 16 factors compared between the two stocks.

How does Omnicell compare to HealthStream?

Omnicell (NASDAQ:OMCL) and HealthStream (NASDAQ:HSTM) are both small-cap health care technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

97.7% of Omnicell shares are held by institutional investors. Comparatively, 69.6% of HealthStream shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Comparatively, 20.4% of HealthStream shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

HealthStream has a net margin of 6.39% compared to Omnicell's net margin of 1.67%. HealthStream's return on equity of 6.47% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
HealthStream	6.39%	6.47%	4.44%

Omnicell has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, HealthStream has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

HealthStream has lower revenue, but higher earnings than Omnicell. HealthStream is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.61	$2.05M	$0.44	95.53
HealthStream	$304.06M	2.73	$18.34M	$0.67	42.42

In the previous week, Omnicell had 2 more articles in the media than HealthStream. MarketBeat recorded 7 mentions for Omnicell and 5 mentions for HealthStream. HealthStream's average media sentiment score of 1.00 beat Omnicell's score of 0.94 indicating that HealthStream is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthStream	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omnicell currently has a consensus target price of $59.86, indicating a potential upside of 42.41%. HealthStream has a consensus target price of $24.00, indicating a potential downside of 15.56%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts plainly believe Omnicell is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Omnicell beats HealthStream on 9 of the 17 factors compared between the two stocks.

How does Omnicell compare to Veradigm?

Omnicell (NASDAQ:OMCL) and Veradigm (NASDAQ:MDRX) are both small-cap health care technology companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

97.7% of Omnicell shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Comparatively, 2.3% of Veradigm shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Omnicell had 6 more articles in the media than Veradigm. MarketBeat recorded 7 mentions for Omnicell and 1 mentions for Veradigm. Veradigm's average media sentiment score of 1.58 beat Omnicell's score of 0.94 indicating that Veradigm is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradigm	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Omnicell currently has a consensus price target of $59.86, suggesting a potential upside of 42.41%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts plainly believe Omnicell is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Omnicell has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.61	$2.05M	$0.44	95.53
Veradigm	$1.53B	0.41	N/A	N/A	N/A

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Veradigm	N/A	N/A	N/A

Omnicell has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Summary

Omnicell beats Veradigm on 13 of the 15 factors compared between the two stocks.

How does Omnicell compare to Hinge Health?

Omnicell (NASDAQ:OMCL) and Hinge Health (NYSE:HNGE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Omnicell has a net margin of 1.67% compared to Hinge Health's net margin of -78.95%. Omnicell's return on equity of 4.00% beat Hinge Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Hinge Health	-78.95%	-310.62%	-71.08%

Omnicell presently has a consensus target price of $59.86, indicating a potential upside of 42.41%. Hinge Health has a consensus target price of $75.80, indicating a potential downside of 10.18%. Given Omnicell's stronger consensus rating and higher possible upside, equities analysts clearly believe Omnicell is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Hinge Health	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.95

In the previous week, Hinge Health had 8 more articles in the media than Omnicell. MarketBeat recorded 15 mentions for Hinge Health and 7 mentions for Omnicell. Omnicell's average media sentiment score of 0.94 beat Hinge Health's score of 0.59 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hinge Health	9 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.7% of Omnicell shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Comparatively, 18.9% of Hinge Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Omnicell has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Hinge Health has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Omnicell has higher revenue and earnings than Hinge Health. Hinge Health is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.61	$2.05M	$0.44	95.53
Hinge Health	$646.34M	10.10	-$528.26M	-$12.34	N/A

Summary

Omnicell beats Hinge Health on 11 of the 17 factors compared between the two stocks.

Get Omnicell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMCL vs. The Competition

Export

Metric	Omnicell	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.91B	$1.83B	$6.89B	$12.59B
Dividend Yield	N/A	N/A	2.66%	6.14%
P/E Ratio	95.53	81.49	27.67	25.40
Price / Sales	1.61	7.35	538.74	101.11
Price / Cash	15.01	25.06	47.99	59.26
Price / Book	1.53	5.85	11.03	6.64
Net Income	$2.05M	-$54.76M	$3.56B	$336.71M
7 Day Performance	6.33%	8.70%	4.11%	4.04%
1 Month Performance	0.29%	2.70%	4.83%	1.63%
1 Year Performance	41.05%	5.81%	36.08%	28.49%

Omnicell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMCL Omnicell	3.4872 of 5 stars	$42.03 +0.2%	$59.86 +42.4%	+40.1%	$1.91B	$1.18B	95.53	3,580	News Coverage
AMN AMN Healthcare Services	1.6977 of 5 stars	$30.40 -1.9%	$25.29 -16.8%	+51.7%	$1.20B	$2.73B	N/A	2,664
WST West Pharmaceutical Services	3.6077 of 5 stars	$329.52 +0.5%	$340.09 +3.2%	+64.1%	$23.17B	$3.07B	44.05	10,800	Analyst Forecast
HSTM HealthStream	3.2884 of 5 stars	$25.36 -1.1%	$24.00 -5.4%	+2.0%	$749.08M	$304.06M	37.85	1,160	Options Volume
MDRX Veradigm	N/A	$5.00 +4.2%	N/A	+6.4%	$611.50M	$1.53B	23.25	8,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMCL) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, HSTM, MDRX, and HNGE

How does Omnicell compare to AMN Healthcare Services?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Summary

How does Omnicell compare to HealthStream?

Summary

How does Omnicell compare to Veradigm?

Summary

How does Omnicell compare to Hinge Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, HSTM, MDRX, and HNGE

How does Omnicell compare to AMN Healthcare Services?

Does the media refer more to AMN or OMCL?

Do analysts prefer AMN or OMCL?

Which has more volatility and risk, AMN or OMCL?

Do institutionals and insiders hold more shares of AMN or OMCL?

Which has better earnings and valuation, AMN or OMCL?

Is AMN or OMCL more profitable?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Which has preferable valuation & earnings, WST or OMCL?

Is WST or OMCL more profitable?

Do insiders and institutionals hold more shares of WST or OMCL?

Which has more risk and volatility, WST or OMCL?

Do analysts recommend WST or OMCL?

Does the media prefer WST or OMCL?

Summary

How does Omnicell compare to HealthStream?

Do institutionals & insiders believe in OMCL or HSTM?

Is OMCL or HSTM more profitable?

Which has more risk & volatility, OMCL or HSTM?

Which has higher valuation and earnings, OMCL or HSTM?

Does the media favor OMCL or HSTM?

Do analysts recommend OMCL or HSTM?

Summary

How does Omnicell compare to Veradigm?

Do insiders and institutionals have more ownership in OMCL or MDRX?

Does the media favor OMCL or MDRX?

Do analysts rate OMCL or MDRX?

Which has preferable valuation & earnings, OMCL or MDRX?

Is OMCL or MDRX more profitable?

Which has more risk & volatility, OMCL or MDRX?

Summary

How does Omnicell compare to Hinge Health?

Is OMCL or HNGE more profitable?

Do analysts recommend OMCL or HNGE?

Does the media prefer OMCL or HNGE?

Do institutionals & insiders hold more shares of OMCL or HNGE?

Which has more volatility and risk, OMCL or HNGE?

Which has higher valuation & earnings, OMCL or HNGE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools